Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Executive Summary
Teva's expansion of its branded drug business will focus on central nervous system therapies, with one of its first regulatory submissions, an NDA for a 40 mg/day dose of multiple sclerosis treatment Copaxone,slated for 2009